Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.00005 par value
-
Shares outstanding
-
7,182,182
-
Total 13F shares
-
235,778
-
Share change
-
-630,246
-
Total reported value
-
$263,958
-
Price per share
-
$1.12
-
Number of holders
-
33
-
Value change
-
-$804,996
-
Number of buys
-
11
-
Number of sells
-
8
Institutional Holders of BRAINSTORM CELL THERAPEUTICS INC. - Common Stock, $0.00005 par value (BCLI) as of Q2 2025
As of 30 Jun 2025,
BRAINSTORM CELL THERAPEUTICS INC. - Common Stock, $0.00005 par value (BCLI) was held by
33 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
235,778 shares.
The largest 10 holders included
GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, Gunderson Capital Management Inc., BlackRock, Inc., LIBERTY WEALTH MANAGEMENT LLC, Weaver Consulting Group, UBS Group AG, Traynor Capital Management, Inc., LPL Financial LLC, and Almanack Investment Partners, LLC..
This page lists
33
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.